Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting.
Thirty-three patients admitted for coronary bypass grafting were randomized to cardiopulmonary bypass with a bubble oxygenator (Cobe or Polystan) or a membrane oxygenator (SciMed). Plasma concentrations of C3 activation products and the terminal complement complex were measured using enzyme immunoassays. Both variables increased almost linearly after onset of cardiopulmonary bypass, with maximal concentrations at closure of the sternum. From a baseline of 7.5 to 12.0 arbitrary units (AU)/mL (medians), the concentrations of C3 activation products increased by 117.5 AU/mL (Cobe), 120.5 AU/mL (Polystan), and 213.3 AU/mL (SciMed). The increase in the membrane group was significantly higher than in the two bubble oxygenator groups (p less than 0.01). From a baseline of 0.9 to 1.3 AU/mL, the concentrations of terminal complement complex increased by 5.4 AU/mL (Cobe), 6.6 AU/mL (Polystan), and 7.7 AU/mL (SciMed) (differences not significant). The higher C3 activation caused by the membrane oxygenator may be explained by differences in flow profile and surface area in contact with blood. The study cannot confirm the general assumption that membrane oxygenators lead to lower complement activation than do bubble oxygenators.
Institute for Experimental Medical Research, Ullevaal Hospital, Oslo, Norway.
V
V
Videm
E
E
Fosse
T E
TE
Mollnes
P
P
Garred
J L
JL
Svennevig
D000368:Aged; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D001026:Coronary Artery Bypass / Q000295:instrumentation*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D010106:Oxygenators / Q000009:adverse effects*; D010107:Oxygenators, Membrane / Q000009:adverse effects*; D011897:Random Allocation
D003176:Complement C3